All In Biotech

Drug Trial Radar · NCT07920211

Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Program Consisting of a Phase 2b Trial and a Phase 3 Trial to Evaluate the Efficacy and Safety of TEV-53408 in Participants With Non-Segmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,020 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,020

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Sep 12, 2030

Study completion Jun 19, 2031

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of these clinical trials is to learn if TEV-53408 can help adults with Non-Segmental Vitiligo (NSV). Vitiligo causes patches of skin to lose their color. The main questions the trials aim to answer are: Can TEV-53408 help bring color back to the skin on the face? Can TEV-53408 help bring color back to the skin on the body? What side effects may happen with TEV-53408? TEV-53408 will be compared with placebo to see if it helps bring color back to the skin. Participants will: Receive TEV-53408 or placebo as an injection under the skin Have their skin checked during the trials Answer questions about how vitiligo affects their daily life Have blood tests and other health checks

Conditions

  • Vitiligo

Interventions

  • TEV-53408 Dose ADrug

    Injectable- Subcutaneous administration.

  • TEV-53408 Dose BDrug

    Injectable- Subcutaneous administration.

  • PlaceboDrug

    Injectable- Subcutaneous administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trial 1: Proportion of Participants Achieving a ≥75% Reduction in Facial Vitiligo Area Scoring Index (F-VASI75)Time frame: Baseline, Week 24
  2. Trial 2: Proportion of Participants Achieving F-VASI75Time frame: Baseline, Week 48
  3. Trial 2: Proportion of Participants Achieving T-VASI50 (US Only)Time frame: Baseline, Week 48

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.